NOW APPROVED
for patients with HER2+ mBC after a prior anti-HER2-based regimen1
For US healthcare professionals.
NEW DATA

NOW APPROVED FOR 2L HER2+ mBC1

Access & Support

Support resources for patients prescribed ENHERTU

Register for Updates

Register for ENHERTU updates and/or request contact from a sales representative

Nurse Corner

Get nurse and patient resources to guide the ENHERTU experience

2L, second line; HER2, human epidermal growth factor receptor 2; mBC, metastatic breast cancer.

 
Indications

ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with:

  • Unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either:
    • In the metastatic setting, or
    • In the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy
  • Locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen

Please click here for full Prescribing Information, including Boxed WARNINGS, and click here for Medication Guide.